Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Microbix Biosystems Inc. (T:MBX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 265 Watline Avenue
Tel: N/A
IR: See website
Key People
Martin A. Marino
Independent Chairman of the Board
Cameron L. Groome
President, Chief Executive Officer, Director
James S. Currie
Chief Financial Officer
Philip J. Casselli
Senior Vice President - Sales and Business Development
Mark Luscher
Senior Vice President - Scientific Affairs
Business Overview
Microbix Biosystems Inc is a Canada-based life science company and manufacturer of viral and bacterial antigens and cell, culture-based biological products and technologies. The Company has developed and acquired two technologies: Kinlytic Urokinase and LumiSort. Kinlytic Urokinase is a biologic thrombolytic drug used to treat blood clots. LumiSort is a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest. The Company's catalogue of antigens covers over 30 bacterial and viral pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.
Financial Overview
For the three months ended 31 December 2020,Microbix Biosystems Inc revenues increased 54% to C$3.2M.Net income totaled C$131K vs. loss of C$585K. Revenuesreflect North America segment increase of 64% to C$1.9M,Europe segment increase of 43% to C$1.3M. Net Incomereflects Selling and development after Employee decrease of45% to C$45K (expense), Interest Other decrease of 88% toC$3K (expense).
Employees: 69 as of Sep 30, 2015
Reporting Currency: Canadian Dollars
Enterprise value: $66.66M as of Dec 31, 2020
Annual revenue (TTM): $11.64M as of Dec 31, 2020
EBITDA (TTM): $0.86M as of Dec 31, 2020
Net annual income (TTM): -$5.51M as of Dec 31, 2020
Free cash flow (TTM): -$1.37M as of Dec 31, 2020
Net Debt Last Fiscal Year: $5.73M as of Dec 31, 2020
Shares outstanding: 110,136,580 as of Mar 5, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization